BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 18182975)

  • 1. HPV and cervical cancer: screening or vaccination?
    Bosch FX; Castellsagué X; de Sanjosé S
    Br J Cancer; 2008 Jan; 98(1):15-21. PubMed ID: 18182975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Vaccination perspective against human papillomavirus and consequences for the screening of uterine cervical neoplasm].
    Delvenne P
    Bull Mem Acad R Med Belg; 2007; 162(10-12):483-8; discussion 489-90. PubMed ID: 18557390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
    Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
    Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
    Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
    J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Human papillomavirus and carcinoma of the cervix vaccines against the human papillomavirus-promise of an efficacious prevention].
    Kohl I
    Klin Mikrobiol Infekc Lek; 2006 Jun; 12(3):91-7. PubMed ID: 17051469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Implementation of HPV vaccination in Germany].
    Schreckenberger C; Kaufmann AM; Schneider A
    Dtsch Med Wochenschr; 2007 Oct; 132(42):2221-4. PubMed ID: 17926251
    [No Abstract]   [Full Text] [Related]  

  • 8. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
    Schiffman M
    Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
    Jenkins D
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cervical carcinoma and the vaccination experience with Cervarix].
    Berberova M
    Akush Ginekol (Sofiia); 2012; 51 Suppl 1():4-5. PubMed ID: 23236670
    [No Abstract]   [Full Text] [Related]  

  • 11. Vaccines against human papillomavirus and cervical cancer: promises and challenges.
    Mahdavi A; Monk BJ
    Oncologist; 2005 Aug; 10(7):528-38. PubMed ID: 16079320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
    Flaherty DK; Alkhateeb FM
    Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of cervical cancer: where immunology meets diagnostics.
    Meijer CJ; Heideman DA; Berkhof H; Snijders PJ
    Immunol Lett; 2009 Feb; 122(2):126-7. PubMed ID: 19100775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
    Prescrire Int; 2008 Jun; 17(95):103-4. PubMed ID: 18623911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of human papilloma virus vaccination in Iceland.
    Oddsson K; Johannsson J; Asgeirsdottir TL; Gudnason T
    Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S; Alain S; Denis F
    Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary and secondary prevention of cervical cancer--opportunities and challenges.
    Markowitz LE; Unger ER; Saraiya M
    J Natl Cancer Inst; 2009 Apr; 101(7):439-40. PubMed ID: 19318638
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccination against human papillomavirus types 16 and 18: the impact on cervical cancer.
    Berkhof J; Bogaards JA
    Future Oncol; 2010 Dec; 6(12):1817-21. PubMed ID: 21142854
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevention of cervical cancer through vaccination of adolescents.
    Pichichero ME
    Clin Pediatr (Phila); 2006 Jun; 45(5):393-8. PubMed ID: 16891270
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.